Exelixis, Inc.

Tularik Limited

Patrick C Kearney

Elena S Koltun

James William Leahy

S David Brown

Hongwang Du

Peiwen Zhou

Wei Xu

Wai Ki Vicky Chan

Moon Jung Kim

John M Nuss

Naing N Aay

Amy Lew Tsuhako

Mohamed Ibrahim

Arlyn Arcalas

Michael Pack

Henry William Beecroft Johnson

Brian Kane

John A Flygare

Jonathan B Houze

Lawrence R McGee

Juan Carlos Jaen

Yong Wang

Timothy David Cushing

Timothy Patrick Forsyth

Lynne Canne Bannen

Jin-Long Chen

Morrison B Mac

Jeff Z Chen

Ping Huang

Steven Marc Rubenstein

Grace Mann

Tai Phat Huynh

Adam Galan

Troy M Swartwood

Brian Hugh Ridgway

Sergey Epshteyn

Gary Lee Lewis

Charles K Marlowe

Jeffrey D Donaldson

William Bajjalieh

Matthew Sangyup Lee

Douglas O Keller

Shi-Chang Miao

Robin Tammie Noguchi

Zerom Tesfai

David Clarence Hager

Robert D Mercer

Fabienne De La Brouse-Elwood

Michael M Morrissey

Neel Kumar Anand

Csaba J Peto

Kenneth D Rice

Tsze Tsang

Joerg Bussenius

Abigail R Kennedy

Charles M Blazey

Craig Stacy Takeuchi

Jean-Claire Limun Manalo

Cristiana A Zaharia

Jeffry Kimo Curtis

Xian Shi

Byung Gyu Kim

Joon Won Jeong

Lisa E Meyr

John Woolfrey

Micheal Morrissey

The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds. 

Inhibitors of PI3K-delta and methods of their use and manufacture

The present invention comprises small molecule inhibitors of phosphatidylinositol 3-kinase (PI3K), which is associated with a number of malignancies such as ovarian cancer, cervical cancer, breast cancer, colon cancer, rectal cancer, and glioblastomas, among others. Accordingly, the compounds of the present invention are useful for treating, preventing, and/or inhibiting these diseases.

Phosphatidylinositol 3-kinase inhibitors and methods of their use

This disclosure relates to sphingosine-1-phosphate (S1P) receptor antagonists, compositions comprising the S1P receptor antagonists and methods for using and processes for making the S1P receptor antagonists. In particular, this disclosure relates to sphingosine-1-phosphate 1 (S1P1) receptor antagonists, compositions comprising the S1P1 receptor antagonist and methods for using the S1P1 receptor antagonist, such as in the treatment of cancer, and processes for making the S1P1 receptor antagonists.

Acetanilide sphingosine-1-phosphate receptor antagonists

This invention relates to certain pyrimidine derivative inhibitors of JAK-2, having Formula (I): wherein D, E, L, Z, R, R, R, and n1 are as defined in the specification, pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof.

4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as JAK-2 modulators and methods of use

A compound having Formula I: or a pharmaceutically acceptable salt thereof, wherein X, R, R and R are as defined in the specification; pharmaceutical compositions thereof; and methods of use thereof. The compounds of Formula I are inhibitors of Casein kinase II (CK2) pathways. 

Pyrimidinones as casein kinase II (CK2) modulators

A compound having Formula I or II (Formula I) or (Formula II), or a pharmaceutically acceptable salt thereof, wherein X, Z, R, R, Rand Rare as defined in the specification; pharmaceutical compositions thereof; and methods of use thereof. 

6-phenylpyrimidinones as PIM modulators

A compound having Formula (I) or a pharmaceutically acceptable salt thereof, wherein X, Rand Rare defined in the specification; pharmaceutical compositions thereof; and methods of use thereof. 

Pyrimidinones as Casein Kinase II (CK2) modulators

This invention relates to the field of protein tyrosine kinases and inhibitors thereof. In particular, the invention relates to inhibitors of JAK-2, pharmaceutical compositions of the compounds for inhibiting JAK-2, methods of inhibiting JAK-2 in a cell, comprising contacting a cell in which inhibition of JAK-2 is desired with a compound or pharmaceutical composition comprising a compound according to the invention. The also comprises methods of treating a disease or condition that involves JAK-2 comprising administering to a patient a pharmaceutical composition comprising a compound according to the invention.

JAK-2 modulators and methods of use

Compounds of formula (I), useful for inhibiting PIM-I and/or PIM-3: and pharmaceutically acceptable salts thereof, wherein Y, Z, R, R, Q, X and Rare as defined above. Pharmaceutical compositions and methods of treating diseases and conditions, such as cancer, are also disclosed. 

Pyridopyrimidinone inhibitors of PIM-1 and/or PIM-3

A multi-well assembly () comprises a multi-well block () and a guide plate (). The multi-well block () has a plurality of wells () each with a fluid-impermeable bottom surface (). The guide plate () has a plurality of fluid passageways () corresponding to the wells () of the multi-well block (). The guide plate () is configured to establish fluid communication between each well () and an associated fluid passageway () when the guide plate () is aligned with the multi-well block ().

Multi-well apparatus

A multi-well assembly according to one embodiment comprises a multi-well block and a guide plate. The multi-well block defines a plurality of wells, with each well having a fluid-impermeable bottom surface. The guide plate defines a plurality of fluid passageways corresponding to the wells of the multi-well block. The guide plate is configured such that, whenever the guide plate is registered with the multi-well block, fluid communication is established between each well and an associated fluid passageway.

Modulators of PPAR&ggr; activity are provided which are useful in pharmaceutical compositions and methods for the treatment of conditions such as type II diabetes and obesity.

PPAR&ggr; modulators

PPAR-&ggr; modulators

Growing community of inventors

San Francisco, CA, United States of America

Patrick C Kearney